flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 just got FDA-approved for disease. This changes everything. January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in type 2 diabetes with CKD. This Oral Semaglutide and Cardiovascular Outcomes

Vitamin B1 and B6 appointments are simple to schedule and designed to fit comfortably into busy routines

G.FordS

Adipotide Adipotide is a synthetic chimeric peptide consisting of a targeting sequence linked to a proapoptotic motif, available as a lyophilized powder for laboratory research

The hormone has far greater timeframe to circulate around the body, bind to receptors, and exert its effects

Cardiometabolic risk minimization: Due to its impact on weight and glucose metabolism, Retatrutide may potentially reduce long-term cardiovascular risk factors (such as high blood pressure), though definitive outcomes are still under investigation